GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (NAS:MRNA) » Definitions » Enterprise Value

Moderna (Moderna) Enterprise Value : $43,562 Mil (As of May. 18, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Moderna Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Moderna's Enterprise Value is $43,562 Mil. Moderna's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-4,767 Mil. Therefore, Moderna's EV-to-EBIT ratio for today is -9.14.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Moderna's Enterprise Value is $43,562 Mil. Moderna's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-4,188 Mil. Therefore, Moderna's EV-to-EBITDA ratio for today is -10.40.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Moderna's Enterprise Value is $43,562 Mil. Moderna's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $5,083 Mil. Therefore, Moderna's EV-to-Revenue ratio for today is 8.57.


Moderna Enterprise Value Historical Data

The historical data trend for Moderna's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Enterprise Value Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 5,612.03 37,290.38 92,542.94 60,451.70 30,628.90

Moderna Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51,159.72 39,000.50 33,235.49 30,628.90 33,513.69

Competitive Comparison of Moderna's Enterprise Value

For the Biotechnology subindustry, Moderna's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moderna's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moderna's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Moderna's Enterprise Value falls into.



Moderna Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Moderna's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Moderna's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna  (NAS:MRNA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Moderna's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=43562.247/-4767
=-9.14

Moderna's current Enterprise Value is $43,562 Mil.
Moderna's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4,767 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Moderna's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=43562.247/-4188
=-10.40

Moderna's current Enterprise Value is $43,562 Mil.
Moderna's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4,188 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Moderna's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=43562.247/5083
=8.57

Moderna's current Enterprise Value is $43,562 Mil.
Moderna's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,083 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Moderna Enterprise Value Related Terms

Thank you for viewing the detailed overview of Moderna's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna (Moderna) Business Description

Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Stephen Hoge officer: President C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James M Mock officer: Chief Financial Officer 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Shannon Thyme Klinger officer: Chief Legal Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Noubar Afeyan director, 10 percent owner C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Arpa Garay officer: Chief Commercial Officer 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephane Bancel director, officer: Chief Executive Officer 320 BENT STREET, CAMBRIDGE MA 02141
Juan Andres officer: See Remarks C/O MODERNA, INC., 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paul Burton officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
David W Meline officer: Chief Financial Officer 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Jorge M Gomez officer: See Remarks C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Sagan director AKAMAI TECHNOLOGIES INC, 8 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Tal Zvi Zaks officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Lori M. Henderson officer: General Counsel and Secretary MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115

Moderna (Moderna) Headlines

From GuruFocus

Q3 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc Clinical Data Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at UBS BioPharma Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Moderna Inc ASCO Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Moderna Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Moderna Inc at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-23-2024